TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of MRI for Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age of patients: up to 80 years.~* Men scheduled for radical prostatectomy due to prostate cancer or men post radical prostatectomy with suspicion of recurrence.~* Patients who are able and willing to give consent and able to have an MRI examination.~Exclusion Criteria:~* Contraindications to MRI including: claustrophobia, weight over 120 kg, implanted ferromagnetic materials or foreign objects, and known intolerance to the MRI contrast agent (e.g. Gadolinium or Dotarem)~* Individuals who are not able or willing to tolerate the required prolonged stationary supine position during imaging (approximately 1 hr.)~* Any rectal pathology preventing probe insertion, (as active proctitis, active ulcerative colitis, fissure ani)~* Any spinal pathology that prohibits maintaining supine position for an hour~* Patients with documented myocardial infarction within one month of protocol entry, and patients with cardiac pacemakers~* Severe cerebrovascular disease (multiple CVA or CVA within 6 months)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: First Time in Man Trial for Friulimicin B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy subjects~* 18-55 years of age~* In good health~Exclusion Criteria:~* Abnormal physical findings of clinical significance at the Screening examination or baseline which would interfere with the objectives of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Experimental arm with increasing dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Metastatic soft tissue or bone sarcoma~* 18 years of age or older~* Adequate blood counts~* Adequate kidney and liver function~* At least 1 but no more than 3 prior systemic therapy regimens for this cancer~* Good performance status - able to carry out work of a light or sedentary nature~Exclusion Criteria:~* Pre-existing hear disease such as congestive heart failure, or arrhythmia known to increase the risk of thromboembolic events (blood clots)~* Blood clot in the last 6 months, known clotting problem or platelet disorder~* History of brain cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SGO Society of Gynecologic Oncologists Data Outcomes Project

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Must have a pelvic mass with surgery taking place.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Novel Induction to Buprenorphine/Naloxone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment with Bicycle Health services~* Aged 18 years old or older~* Diagnosis of opioid use disorder confirmed by DSM-5 criteria~* In no/mild withdrawal at the time of intake~* Need to undergo induction to buprenorphine from a full opioid agonist~* Use of full opioid agonists not directly from a pharmacy within the last 24 hours~* Pharmacy stock check of 2 mg film/tablet done before visit~* Willingness and ability to follow study protocols, and the ability to provide informed consent~Exclusion Criteria:~* Known allergy or sensitivity to buprenorphine/naloxone~* Any circumstance that precludes the need for induction~* In moderate to severe withdrawal at the time of intake~* Severe or complex medical/psychiatric comorbidity that requires a customized induction schedule or surveillance~* Any element that would exclude an individual from Bicycle Health services in general (e.g., homelessness, severe untreated mental illness)~* Patients requesting specific induction technique~* Patients who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traditional Induction Arm (Type: ACTIVE_COMPARATOR): In this arm, study participants will wait until they have significant opioid withdrawal (SOWS score \>=17) prior to starting buprenorphine. Participants will then started with 2 mg sublingual and escalate to a maximum of 12 mg on the first day depending on withdrawal symptoms. On day 2, the participant will take same dose as the total dose taken on day 1, and continue that dose daily until reevaluation.
- Microdosing Induction Arm (Type: ACTIVE_COMPARATOR): In this arm, study participants will not wait until they have significant opioid withdrawal. They will take 0.5 mg buprenorphine on day 1, 2 mg on day 2, 4 mg on day 3, 6 mg on day 4, 8 mg on day 5 and 12 mg starting on day 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PlayGait: A Dynamic Exoskeleton

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3 - 4 years (at time of informed consent)~* Hemiplegic cerebral palsy~* If child uses an ankle-foot orthosis (AFO), parent/caregiver is willing to have the child stop wearing their prescribed AFO during data collections (lab sessions and two 7-day periods at home)~* Ability to walk at least 10 meters without the use of assistive devices or AFOs~* Ability to walk at least 1 minute without the use of assistive devices or AFOs~* Stiff knee gait - less than normal knee flexion during swing phase~* Hip flexion passive range of motion contracture less than 20 degrees~* Gross Motor Function Classification System (GMFCS) Levels I-II~* Modified Ashworth Scale (MAS) \<=2 for the gastrocnemius soleus, rectus femoris, and hamstrings~* Family has resources to attend all study sessions (transportation, schedule)~* Ability to speak and understand in English~Exclusion Criteria:~* Orthopedic surgery in the last year~* Foster children or wards of the state~* Use wheelchair or stroller mobility as their primary method of independent mobility~* Severe visual impairment such that the visual impairment itself functionally limits mobility~* Phenol or Botox injections to the legs in the last 3 months~* Uncontrolled seizure disorder, defined as any seizure in the last 3 months that influenced mobility skills and function (seizures which did not affect mobility are acceptable)~* Lower limb fracture in the last 3 months~* Planned surgery or changes to movement disorder medication during the study period~* Inability to understand directions sufficiently to complete the study assessments~* Cognitive, behavioral, or any other issues that may not allow for effective study participation~* Unwilling to complete the study protocol

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- PlayGait (Exoskeleton) (Type: EXPERIMENTAL): Experimental lower-limb device.
- Baseline (Type: ACTIVE_COMPARATOR): Baseline condition without using any prescribed lower-limb orthoses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Calfactant for Direct Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Respiratory failure due to diffuse infectious pneumonia, aspiration, near drowning, smoke inhalation or industrial gas~2. Less than 48 hours of mechanical ventilation~3. Informed consent~Exclusion Criteria:~1. Pre-existing lung disease~2. coma~3. limited therapeutic goals (do not resuscitate, etc.)~4. failure of another vital organ

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Calfactant treatment
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients age 18-55~* Signs or symptoms consistent with sexually transmitted infection~* Medical provider willing to consider the result of the rapid turnaround test in decision to treat for gonorrhea/chlamydia~* Must have a urine specimen obtained and a pelvic exam performed as part of the anticipated standard of care evaluation~* Provides informed consent~Exclusion Criteria:~* Signs of systemic infection~* Patient in whom the provider is unwilling to consider the result of the rapid turnaround test~* Patient who reports being treated for either gonorrhea or chlamydia in the preceding 3 months~* Patients undergoing evaluation for sexual assault~* Patients that are known to be pregnant or express concern that they may be pregnant~* Incarcerated patients~* Students/Employees of the facility~* Presence of any other condition(s) that the investigator feels makes the patient unsuitable for study inclusion.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Rapid Turnaround Test (Type: EXPERIMENTAL): Patients randomized to this arm will be tested for a sexually transmitted infection (STI) with both the rapid nucleic acid amplification test (NAAT) as well as the conventional polymerase chain reaction (PCR) test. The results from the rapid turnaround test will guide providers on treatment decisions for a possible STI. The results from the PCR test will be used to verify the results of the rapid turnaround test.
- Usual Care (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will be tested for a sexually transmitted infection (STI) using the conventional PCR test. The results from the PCR test normally take approximately 48-72 hours and these patients will likely receive treatment based on the decision of the clinical provider. The results from the PCR test will be used to verify the decision of the clinical provider to treat or withhold treatment for a possible STI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Combination Non Steroidal Antiinflammatory Drugs and Narrowband UVB Treatment in Non-Photoadapters

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should have a diagnosis of vitiligo.~* Patients who are identified as nonphotoadapters (those who cannot increase NBUVB dose past 400 mJ/cm2) will be recruited for the study~Exclusion Criteria:~* Patients with the daily ibuprofen use, history of renal disease, cardiac disease, gastric uler and bleeding disorder will be excluded from the study. Patients with a history of lupus erythematosus and other photosensitivity disorders will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Intervention group (Type: EXPERIMENTAL): There is one group in this study and they will receive ibuprofen 400 mg before their narrow band UVB phototherapy session which occurs two to three times weekly. The treatment dose of NBUVB will start off at 150 mJ/cm2 and will be increased 10% as tolerated til the patient reaches 700 mJ/cm2. They will receive ibuprofen before each phototherapy session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria include:~* Clinical diagnosis of advanced emphysema~* Age \> 18 years at the time of initial presentation~* Clinically significant dyspnea (MRC Dyspnea \>/= 2)~* Laboratory tests within protocol-specified ranges~* Pulmonary function tests~Exclusion Criteria include:~* Alpha-1 protease inhibitor deficiency verified by a serum level of \<80mg% or knowledge of PI\*ZZ genotype~* Tobacco use within 16 weeks of the initial clinic visit~* Body mass index \< 15 kg/m2 or \> 35 kg/m2~* Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis~* Allergy to fish or pork products or sensitivity to tetracycline~* FEV1 \<20% predicted with DLCO \<20% predicted or homogeneous disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single (Type: EXPERIMENTAL): BLVR Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: MINIMALLY INVASIVE SURGERY in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* require primary uni- or bilateral total knee arthroplasty; available for 2 year follow up; provide informed consent; is in stable health for cardio-pulmonary conditions.~Exclusion Criteria:~* inefficient femoral or tibial bone stock; BMI \>35; fixed flexion deformity \>15 degrees; knee flexion of \<90 degrees; varus/valgus deformity \>20 degrees; active local infection; conditions that would compromise the 2 years follow up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Minimal Invasive Surgery, (Type: EXPERIMENTAL): None
- Standard Surgical Technique (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Dexmedetomidine or Propofol on ICU Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age 18 years or older) in a state of delirium (hyperactive ore mixed type) upon detection in the ICU (i.e., ICDSC \>3).~Exclusion Criteria:~* Hypersensitivity to the active substance~* Advanced heart block (grade 2 or 3) unless implanted pacemaker~* Uncontrolled hypotension~* Severe cardiac dysfunction~* Bradycardia~* Egg allergy~* Soybean/soy allergy~* Age below 18 years~* Terminal state~* Pregnancy~* Active psychosis (of non organic origin = functional disturbances)~* Status epilepticus or postictal states following seizures on EEG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
- Propofol (Type: ACTIVE_COMPARATOR): Standard therapy for ICU delirium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>18 years~* With well compensated cirrhosis and hepatocellular carcinoma meeting UCSF criteria~* Without general contraindication to LT~* Written informed consent.~Exclusion Criteria:~* Patients that already had TACE~* Or other local treatment for HCC~* Or neoadjuvant systemic chemotherapy~* Or planned living donor~* Or non arterialized lesion(s)~* Or Contraindication to DC-BeadsR~* Or allergy to contrast agents~* Or contraindication to Doxorubicin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-arterial administration of DC BeadsR (Type: EXPERIMENTAL): Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
- Control (Type: NO_INTERVENTION): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intraoperative Magnesium Sulfate Infusion on the Postoperative Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 18-65 year-old-patient (ASA I-II) who are planned to undergoing day surgery~Exclusion Criteria:~* ASA class ≥ III~* suspected imbalance of electrolyte~* myocardial damage or conduction delay~* myasthenia gravis or other neuromuscular disease~* impaired renal function~* already using any type of analgesia~* denial of participating in the study or not giving the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Normal saline group (Type: PLACEBO_COMPARATOR): after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
- Magnesium group (Type: ACTIVE_COMPARATOR): after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy